Search results
Results From The WOW.Com Content Network
The MVC COVID-19 vaccine (Chinese: 高端新冠肺炎疫苗; pinyin: Gāoduān xīnguàn fèiyán yìmiáo; Wade–Giles: Kaotuan hsinkuan feiyen imiao), designated MVC-COV1901 and also known as the Medigen COVID-19 vaccine, is a protein subunit COVID-19 vaccine developed by Medigen Vaccine Biologics Corporation in Taiwan, American company ...
Medical uses It requires two doses 21 days apart given by intramuscular injection. Pharmacology COVAX-19 is a recombinant protein subunit. History Vaxine began work on a COVID-19 vaccine in January 2020. After developing a vaccine adjuvant the company decided to focus on a "recombinant protein-based vaccine". A phase 1 human trial started in June 2020. The phase 1 trial involved 40 ...
t. e. COVI-VAC ( codenamed CDX-005) is a COVID-19 vaccine developed by Codagenix, Inc. In December 2020, COVI-VAC started a Phase I clinical trial, involving 48 participants. The trial was scheduled to complete in June 2021, with results to be reported by May 2022. [2] [3] On September 29, 2021, Codagenix presented positive phase 1 data for ...
The phase II concluded in April 2021. In April 2021, the Drugs Controller General of India permitted the vaccine candidate to start phase III clinical trials. A total of 1,268 healthy participants between the age of 18 and 80 years to be selected from 15 sites across India for the trial and intended to be part of a larger global Phase III study.
The Sanofi–GSK COVID‑19 vaccine is a recombinant protein subunit vaccine containing the SARS-CoV-2 spike protein, which is produced in insect cells via a baculovirus vector. It also includes an adjuvant made by GSK. It uses the same technology as Sanofi's Flublok influenza vaccine. [7] [8]
History In June 2020, Sanofi, after lagging behind its competitors, "accelerated" the development of the vaccine via the smaller biotech firm Translate Bio, with a US $425 million partnership. Development of the vaccine halted in September 2021, with Sanofi citing the difficulty of running placebo-controlled studies with other mRNA vaccines (such as Pfizer's and Moderna's) already on the ...
Valneva COVID-19 vaccine is a COVID-19 vaccine developed by French biotechnology company Valneva SE in collaboration with the American biopharmaceutical company Dynavax Technologies. [6] [7] [8] In April 2022, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) approved the vaccine, being the first in the world to do ...
ARCT-154, also known as VBC-COV19-154 in Vietnam, is a COVID-19 vaccine candidate developed by Arcturus Therapeutics. [1] [2] For its development, Arcturus collaborated with Vinbiocare, a Vietnamese company, for support with clinical trials and manufacturing.
e. ZF2001, trade-named Zifivax or ZF-UZ-VAC-2001, is an adjuvanted protein subunit COVID-19 vaccine developed by Anhui Zhifei Longcom in collaboration with the Institute of Microbiology at the Chinese Academy of Sciences. [1] [2] The vaccine candidate is in Phase III trials with 29,000 participants in China, Ecuador, Malaysia, Pakistan, and ...
In Spring 2021, as vaccines became available to professional athletes, several professional leagues encountered substantial vaccine hesitancy among players. In August 2021 the Atlanta Falcons, a football team from the National Football League (NFL) located in Atlanta, Georgia, became the first NFL team to report being fully vaccinated.